Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS) — HTLV-OBS

HTLV-1 Infection Clinical Trial

Official title:
Caractérisation Clinico- Biologique et Survie Des Patients Porteurs d'Une lymphoprolifération HTLV-1 Induite (ou Lymphome/leucémie lié au Virus HTLV-1) et Des Patients infectés Par le Virus HTLV-1

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the outcome (survival) of Adult T-cell leukemia / lymphoma (ATL) patients who receive or not specific treatment for their hemopathy (cohort 1) and the outcome (survival) of HTLV-1 chronically infected patients with / without extra-haematological disorders (cohort 2).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05237245
Study type	Observational
Source	Assistance Publique - Hôpitaux de Paris
Contact	Ambroise MARCAIS, MD
Phone	+33 1 44 49 46 99
Email	ambroise.marcais@aphp.fr
Status	Recruiting
Phase
Start date	March 23, 2022
Completion date	March 2027

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03075553` - Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma	Phase 2
Completed	`NCT01581567` - Neuroimmunology Branch Repository
Completed	`NCT02631746` - Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma	Phase 2
Recruiting	`NCT04301076` - Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)	Phase 1